Abstract We describe the validation of a serum-based test developed by Rules-Based Medicine which can be used to help confirm the diagnosis of schizophrenia. In preliminary studies using multiplex immunoassay profiling technology, we identified a disease signature comprised of 51 analytes which could distinguish schizophrenia (n = 250) from control (n = 230) subjects. In the next stage, these analytes were developed as a refined 51-plex immunoassay panel for validation using a large independent cohort of schizophrenia (n = 577) and control (n = 229) subjects. The resulting test yielded an overall sensitivity of 83% and specificity of 83% with a receiver operating characteristic area under the curve (ROC-AUC) of 89%. These 51 immunoassays and the associated decision rule delivered a sensitive and specific prediction for the presence of schizophrenia in patients compared to matched healthy controls.
Discussion
No comments yet...Be the first to comment.
I serve as a peer reviewer for Libertas Academica and I would say LA is a great publisher to work with. The online review system is easy to navigate and the review process is straightforward. I am really looking forward to reviewing more manuscripts and submitting my own results as well in the future.Dr Jianxiong Jiang (Department of Pharmacology, Emory University School of Medicine, Atlanta, GA, USA) What our authors say
Copyright © 2010 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)